{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:54:26Z","timestamp":1792068866897,"version":"4.4.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100012542","name":"Sichuan Provincial Science and Technology Support Program","doi-asserted-by":"publisher","award":["2026NSFSC1743"],"award-info":[{"award-number":["2026NSFSC1743"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.bmcl.2026.130786","type":"journal-article","created":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T22:11:41Z","timestamp":1790547101000},"page":"130786","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Discovery of Fisetin as a potent and cell-active ACVR2A inhibitor"],"prefix":"10.1016","volume":"142","author":[{"given":"Xiaohan","family":"Bu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengzhe","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengyong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2026.130786_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2024.171149","article-title":"Recent advances in peptide-based therapies for obesity and type 2 diabetes","volume":"173","author":"Bailey","year":"2024","journal-title":"Peptides"},{"key":"10.1016\/j.bmcl.2026.130786_bb0010","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41574-019-0176-8","article-title":"Obesity: global epidemiology and pathogenesis","volume":"15","author":"Bl\u00fcher","year":"2019","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.bmcl.2026.130786_bb0015","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(25)00355-1","article-title":"Global, regional, and national prevalence of adult overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the global burden of disease study 2021","volume":"405","author":"Ng","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.bmcl.2026.130786_bb0020","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.bmcl.2026.130786_bb0025","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S0140-6736(23)02750-2","volume":"403","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.bmcl.2026.130786_bb0030","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with Tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne","year":"2024","journal-title":"Jama"},{"key":"10.1016\/j.bmcl.2026.130786_bb0035","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41573-021-00337-8","article-title":"Anti-obesity drug discovery: advances and challenges","volume":"21","author":"M\u00fcller","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmcl.2026.130786_bb0040","first-page":"618","article-title":"Tirzepatide (Mounjaro\u00ae) : a GIP\/GLP-1 receptor dual agonist for the treatment of type 2 diabetes","volume":"80","author":"Scheen","year":"2025","journal-title":"Rev Med Liege"},{"key":"10.1016\/j.bmcl.2026.130786_bb0045","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.3748\/wjg.v30.i48.5205","article-title":"GLP-1, GIP\/GLP-1, and GCGR\/GLP-1 receptor agonists: novel therapeutic agents for metabolic dysfunction-associated steatohepatitis","volume":"30","author":"Singh","year":"2024","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.bmcl.2026.130786_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107927","article-title":"Glucagon-like peptide-1 receptor agonists and muscle mass effects","volume":"220","author":"Ceasovschih","year":"2025","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.bmcl.2026.130786_bb0055","doi-asserted-by":"crossref","unstructured":"Wilding, J.P., et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 384, 989\u20131002 (2021).","DOI":"10.1056\/NEJMoa2032183"},{"key":"10.1016\/j.bmcl.2026.130786_bb0060","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/mt.2014.221","article-title":"Development of novel activin-targeted therapeutics","volume":"23","author":"Chen","year":"2015","journal-title":"Mol Ther"},{"key":"10.1016\/j.bmcl.2026.130786_bb0065","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1096\/fj.13-245894","article-title":"Elevated expression of activins promotes muscle wasting and cachexia","volume":"28","author":"Chen","year":"2014","journal-title":"FASEB J"},{"key":"10.1016\/j.bmcl.2026.130786_bb0070","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1128\/MCB.06575-11","article-title":"Blockade of the activin receptor IIb activates functional brown adipogenesis and thermogenesis by inducing mitochondrial oxidative metabolism","volume":"32","author":"Fournier","year":"2012","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.bmcl.2026.130786_bb0075","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1128\/MCB.01307-13","article-title":"An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy","volume":"34","author":"Lach-Trifilieff","year":"2014","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.bmcl.2026.130786_bb0080","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.33457","article-title":"Effect of Bimagrumab vs placebo on body fat mass among adults with type 2 diabetes and obesity: a phase 2 randomized clinical trial","volume":"4","author":"Heymsfield","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.bmcl.2026.130786_bb0085","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/s41591-026-04204-0","article-title":"Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial","volume":"32","author":"Heymsfield","year":"2026","journal-title":"Nat Med"},{"key":"10.1016\/j.bmcl.2026.130786_bb0090","doi-asserted-by":"crossref","unstructured":"ZHANG, R., et al. 861-P: targeting activin type II receptors\u2014develop monoclonal antibodies LAE102, LAE103, and LAE123 as candidate therapeutics for muscle growth and fat reduction. Diabetes 74(2025).","DOI":"10.2337\/db25-861-P"},{"key":"10.1016\/j.bmcl.2026.130786_bb0095","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1182\/blood-2006-07-034124","article-title":"Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells","volume":"109","author":"David","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bmcl.2026.130786_bb0100","doi-asserted-by":"crossref","first-page":"15794","DOI":"10.1074\/jbc.M109.002881","article-title":"Bone morphogenetic protein (BMP) and activin type II receptors balance BMP9 signals mediated by activin receptor-like kinase-1 in human pulmonary artery endothelial cells","volume":"284","author":"Upton","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmcl.2026.130786_bb0105","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/mus.25268","article-title":"Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: results of a randomized, placebo-controlled clinical trial","volume":"55","author":"Campbell","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.bmcl.2026.130786_bb0110","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1074\/jbc.M114.604397","article-title":"Small molecules dorsomorphin and LDN-193189 inhibit myostatin\/GDF8 signaling and promote functional myoblast differentiation","volume":"290","author":"Horbelt","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmcl.2026.130786_bb0115","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1080\/10717544.2016.1245366","article-title":"Enhanced oral bioavailability and anticancer efficacy of fisetin by encapsulating as inclusion complex with HP\u03b2CD in polymeric nanoparticles","volume":"24","author":"Kadari","year":"2017","journal-title":"Drug Deliv"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X26002532?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X26002532?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:36:27Z","timestamp":1792067787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X26002532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":23,"alternative-id":["S0960894X26002532"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2026.130786","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of Fisetin as a potent and cell-active ACVR2A inhibitor","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2026.130786","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"130786"}}